Blog
Two Pills, No Chemo: Tumors Shrank in 82% of Pancreatic Cancer Patients in an Early Trial
In an early trial presented at ESMO 2026, two once-daily pills — vopimetostat and daraxonrasib — shrank tumors in 82% of patients with a genetic subtype of advanced pancreatic cancer, most on their third line of therapy. What the results mean, the side effects, and the Phase 3 test that comes next.
Chemotherapy's Burden Rivals the Cancer Itself: 119 Patients Speak Out
A survey of 119 U.S. endometrial cancer patients, presented at ESMO 2026, found 70% felt the burden of chemotherapy was almost as much as the burden of the cancer itself — fatigue 93%, nausea 82%, muscle cramps 76%, and 59% who felt unprepared. Here is what patients reported, in plain language, and how to prepare.